Wednesday Sessions Evaluations Logo

  • Wednesday Sessions Evaluations

    Psychedelic Science 2025

  • Instructions

  • Use this form to complete evaluations for each workshop you attended. 

    • Pages are linked in tabs at the top of this page.
    • You can save the form and return to it at any time. When you save the form, you will be prompted to either create an account using your email address or sign up with Google. Alternatively, you can skip creating an account and copy your unique form link. If you create an account, you will receive an email to verify your account and a second email with your form link. Either option will save your progress.
    • Please complete (submit) only one form per person by July 4, 2025.

  • Learner Information

  • Wednesday, June 18

    • 20 Years Of Human Neuroscience Research With Psychedelics: Lessons And Foundations For The Future Of The Field 

    • At the end of the session, the learner will be able to:

      1. Describe how psychedelics work in the brain.

      2. Explain the clinical utility of psilocybin and MDMA.

      3. Explain how policy changes might be effected to allow more clinical research and treatment.

    • Listening To Public Opinion: Findings From The Second BCSP National Survey 

    • At the end of the session, the learner will be able to:

      1. Identify key trends in public opinion on psychedelics, as revealed by the 2023 and 2025 BCSP National Surveys, to better understand evolving patient perspectives and potential barriers or facilitators to treatment acceptance.

      2. Describe how public opinion data can inform the development of psychedelic policies at various levels of government, enabling clinicians and mental health professionals to advocate for evidence-based practices and navigate the changing legal landscape surrounding psychedelic-assisted therapies.

    • Psychedelics For Veterans: The Latest Research And What It Means For Healing The Veteran Community 

    • At the end of the session, the learner will be able to:

      1. Describe the neurobiological mechanisms of action of psychoplastogens, including their effects on neuroplasticity and large-scale brain network dynamics.

      2. Discuss preliminary clinical findings from a psilocybin-assisted therapy trial for PTSD, including transdiagnostic outcomes such as improvements in moral injury, meaning, and interpersonal connection.

    • Assessing The Evidence For Evidence-Based Therapies In PAT 

    • At the end of the session, the learner will be able to:

      1. Compare and contrast directive evidence-based therapies (e.g., CBT, PE) with non-directive, inner-directed approaches (IDA) within the context of psychedelic-assisted therapy, highlighting theoretical and clinical implications.

      2. Describe current research methodologies and outcomes related to the integration of structured psychotherapeutic models into psychedelic-assisted treatment frameworks for various mental health conditions.

    • Expanding The Lens: Mechanisms, Models & Modes - Transdiagnostic Potential Of Psychedelic Medicines 

    • At the end of the session, the learner will be able to:

      1. Identify at least three to four broad schools of thought in modeling the therapeutic effects of psychedelics: structural neuroplasticity/chemotherapeutic as seen in pre-clinical/animal inflammation work; cortical reorganization seen via neural circuit work in the REBUS model; psychosocial reframing dynamics via a trauma-informed lens; critical period reopening combined with adjunctive therapies.

      2. Identify how different models might impact the treatment approach to different conditions, i.e. major depressive disorder vs TBI, Long COVID vs PTSD, cluster headache vs fibromyalgia, phantom-limb pain vs OCD.

    • Studying Psychedelics, Safety, And Risk 

    • At the end of the session, the learner will be able to:

      1. Describe the lasting adverse effects that can occur after psychedelic experiences, including their frequency and potential causes.

      2. Explain results from surveys of naturalistic use of psychedelics.

    • Reflections On 20 Years As A Psychedelic Researcher 

    • At the end of the session, the learner will be able to:

      1. Describe the rationale and findings of the NYU Psilocybin Cancer Project. which demonstrated psilocybin's profound impact on existential distress in patients with life-threatening cancer.

      2. Explain the MDMA-assisted therapy for PTSD and the development of psilocybin-assisted therapy study for alcohol use disorder.

    • Integrating Psychedelic Coursework Into Higher Education 

    • At the end of the session, the learner will be able to:

      1. Describe resources and best practices for introducing psychedelic therapy curriculum to higher education students, especially in clinical disciplines.

      2. List potential benefits and drawbacks of offering experiential training with psychedelics, ketamine, or practices such as breathwork.

    • Studying Global Culture And Psychedelics 

    • At the end of the session, the learner will be able to:

      1. Compare patterns of psychedelic access and use across various regions and countries.

      2. Discuss the prevalence of use of specific psychedelics in real world settings.

    • Psilocybin Desynchronizes The Human Brain 

    • At the end of the session, the learner will be able to:

      1. Describe the effects of a high dose of psilocybin on brain activity during rest, during task performance, and in the weeks that follow.

      2. Discuss how psilocybin impacts receptors and neural circuits.

    • Addressing Myths And Misconceptions About MDMA Assisted Therapy 

    • At the end of the session, the learner will be able to:

      1. Describe the inner-directed therapy approach that was used in the Phase 2 and 3 clinical trials conducted by MAPS PBC / Lykos Therapeutics.

      2. Describe the concept of the Inner Healing Intelligence and the role it is theorized to play in MDMA-assisted psychotherapy.

      3. Describe the role of the therapeutic alliance in the complex relational dynamics of MDMA-assisted therapy.

      4. Describe the rationale for de-centering the role of the therapist in MDMA-assisted therapy.

    • Neural Mechanisms Of Psychedelic-Induced Changes In Consciousness 

    • At the end of the session, the learner will be able to:

      1. Describe the cognitive mechanisms underlying psychedelics’ therapeutic potential.

      2. Identify neural mechanisms of action of psychedelics in healthy controls.

      3. Discuss therapeutic mechanisms of psychedelics at the psychological, brain networks, and molecular levels.

    • Five-Year Outcomes From A Trial Of Psilocybin-Assisted Therapy For Major Depressive Disorder 

    • At the end of the session, the learner will be able to:

      1. Discuss the long-term clinical outcomes of psilocybin therapy for people with major depressive disorder.

      2. List the ways that trial participants report lasting impact of psilocybin therapy.

    • Changes In Brain Glucose Metabolism After DMT And Harmine Administration: A Human [¹⁸F]Fdg-Pet Study 

    • At the end of the session, the learner will be able to:

      1. Describe new findings on the effects of DMT and harmine on cerebral glucose metabolism in a healthy population.

      2. Discuss the recent developments of a new DMT and harmine drug formulation for oromucosal uptake.

    • Bridging The Fields Of Psychology And Psychedelic-Assisted Therapy 

    • At the end of the session, the learner will be able to:

      1. Describe the current state of psychedelic use in the United States, in clinical and non-clinical settings.

      2. Identify and describe various ways psychologists can effectively support clients, through harm reduction and psychedelic-assisted therapy.

      3. List potential pathways forward for the field of psychology, including setting standards of care for psychedelic-assisted therapy.

    • Introduction To Psychedelic Neuroscience 

    • At the end of the session, the learner will be able to:

      1. Explain how the REBUS model accounts for psychedelic experiences and their therapeutic efficacy.

      2. Describe how the concept of entropy relates to psychedelic brain and psychological effects.

      3. Identify open questions and contentions in psychedelic neuroscience.

    • Psychedelic Frontiers At The National Institutes Of Health: NIH-Funded Studies, Research Opportunities, And Priorities 

    • At the end of the session, the learner will be able to:

      1. Describe the special methodological and logistical challenges involved in academic research on psychedelics.

      2. Discuss the approaches that recent NIH-funded studies have taken to deal with these challenges.

    • Psychedelic Therapy Clinical Trials With Veterans 

    • At the end of the session, the learner will be able to:

      1. Describe global research protocols involving MDMA-assisted group therapy.

      2. Compare and contrast different protocols for different populations.

    • Studies And Discussion Of Ketamine-Assisted Therapy 

    • At the end of the session, the learner will be able to:

      1. Assess the current body of clinical research on ketamine-assisted therapy, including its efficacy, mechanisms of action, and safety profile across various psychiatric conditions.

      2. Discuss ethical, practical, and regulatory considerations in the implementation of ketamine-assisted therapy within contemporary mental health care settings.

    • Cellular And Molecular Antidepressant Actions Of Psychedelics 

    • At the end of the session, the learner will be able to:

      1. Understand the epigenetic mechanisms by which ketamine and MDMA may exert lasting effects on brain function and psychiatric symptoms.

      2. Explore the implications of brain-targeted epigenetic biomarkers for developing precision medicine strategies in psychedelic-assisted therapy.

    • Studies And Discussion Of Ketamine-Assisted Therapy 

    • At the end of the session, the learner will be able to:

      1. Describe the effectiveness of subcutaneous ketamine in treating major depression and suicidal ideation.

      2. Discuss the associated biological changes mediated by the intervention, and discussing its implementation within the Brazilian public healthcare system.

    • Listening To Lead: How A Community-Informed Psilocybin Study Is Guiding New Mexico’s Regulated Model 

    • At the end of the session, the learner will be able to:

      1. Identify the role of community engagement, group psychedelic-assisted therapy, peer navigators, and expanded integration in a community-rooted feasibility and implementation project for a model to support equity and access in New Mexico.

      2. Discuss the potential of group psilocybin assisted therapy for PTSD in veterans, first responders, substance use disorders, and people with sexual trauma.

      3. Describe the evolving state regulated model for therapeutic psilocybin in New Mexico.

    • Emerging Trial Results Of Cognitive Therapy Interventions 

    • At the end of the session, the learner will be able to:

      1. Explain the rationale for manualizing and empirically testing the psychotherapy component of psychedelic-assisted therapies.

      2. Discuss the preliminary acceptability and feasibility results pertaining to an open trial of psilocybin-assisted cognitive behavioral therapy for major depressive disorder.

    • Cellular And Molecular Antidepressant Actions Of Psychedelics 

    • At the end of the session, the learner will be able to:

      1. Analyze the current rationale and preliminary evidence for using psilocybin to target anhedonia

      2. Discuss the current data on using psilocybin concurrently with serotonergic antidepressants for the treatment of depression.

    • A Machine Learning Perspective On Psychedelics And Psychopathology 

    • At the end of the session, the learner will be able to:

      1. Describe the current leading computational models of how psychedelics effect the brain and induce therapeutic effects.

      2. Explain how psychedelics influence structures and signalling pathways in the brain.

  • Final Submission

    Click 'Submit' once you have completed this form. You may 'Save' multiple times but only 'sbumit' once.
  • Should be Empty: